LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Gesloten

8.72 13.25

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.97

Max

8.91

Belangrijke statistieken
By Trading Economics
Inkomsten	4.2M -23M
Winstmarge	-2,027.003
Werknemers	83
EBITDA	6.6M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+77.13% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	8.3M 595M
Vorige openingsprijs	-4.53
Vorige sluitingsprijs	8.72

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 dec 2025, 17:29 UTC

Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 dec 2025, 16:47 UTC

Belangrijke Marktbewegers

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 dec 2025, 16:10 UTC

Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19 dec 2025, 22:33 UTC

Winsten

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 dec 2025, 22:19 UTC

Winsten

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 dec 2025, 21:48 UTC

Acquisities, Fusies, Overnames

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dec 2025, 21:44 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 dec 2025, 21:38 UTC

Winsten

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 dec 2025, 21:00 UTC

Marktinformatie

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 dec 2025, 20:23 UTC

Marktinformatie

Oil Futures End Down Week on Up Note -- Market Talk

19 dec 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 dec 2025, 18:38 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 dec 2025, 18:00 UTC

Marktinformatie

Winsten

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 dec 2025, 17:41 UTC

Winsten

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 dec 2025, 17:24 UTC

Marktinformatie

Winsten

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 dec 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

19 dec 2025, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

19 dec 2025, 16:29 UTC

Winsten

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 dec 2025, 16:20 UTC

Acquisities, Fusies, Overnames

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 dec 2025, 16:19 UTC

Acquisities, Fusies, Overnames

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 dec 2025, 16:18 UTC

Acquisities, Fusies, Overnames

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 dec 2025, 16:16 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

19 dec 2025, 16:16 UTC

Marktinformatie

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 dec 2025, 16:05 UTC

Acquisities, Fusies, Overnames

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dec 2025, 16:04 UTC

Acquisities, Fusies, Overnames

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dec 2025, 15:37 UTC

Marktinformatie

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19 dec 2025, 15:21 UTC

Marktinformatie

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19 dec 2025, 15:09 UTC

Marktinformatie

Gold Flat But Set for Weekly Gains -- Market Talk

19 dec 2025, 15:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 dec 2025, 15:09 UTC

Winsten

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

77.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.71 USD 77.13%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.